CST, 5013P, p44/42 MAPK (Erk1/2) (137F5) Rabbit Monoclonal Antibody (Biotinylated)

Monoclonal Antibody for studying ERK1/ERK2. Validated for Western Blotting,Peptide ELISA (DELFIA). Highly specific and rigorously validated in-house, p44/42 MAPK (Erk1/2) (137F5) Rabbit Monoclonal Antibody (Biotinylated) (CST #5013) is ready to ship. Product Usage Information Biotinylated antibodies are ideal for immunoassay technologies and high-throughput ELISA platforms that require antibody pairs where both antibodies are from the same host. Platforms utilizing biotinylated antibodies include, but are not limited to, MSD, xMAP, Quanterix Simoa, AlphaLISA, AlphaScreen, HTRF, LANCE, and TR-FRET. Optimal dilutions/working concentrations should be determined by the end user. Please contact us if you require the antibody clone biotinylated at a different concentration, a carrier-free formulation, or a more customized packaging solution." Storage Supplied in 140 mM NaCl, 3 mM KCl, 10 mM sodium phosphate (pH 7.4) dibasic, 2 mM potassium phosphate monobasic, 2 mg/mL BSA, and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity p44/42 MAPK (Erk1/2) (137F5) Rabbit Monoclonal Antibody (Biotinylated) detects endogenous levels of total p44/42 MAP kinase (Erk1/Erk2) protein. This antibody does not cross-react with JNK/SAPK or p38 MAP kinase. Species Reactivity: Human, Mouse, Rat, Hamster, Monkey, Mink, D. melanogaster, Zebrafish, Bovine, Dog, Pig, C. elegans Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the C-terminus of rat p44 MAP kinase. Background Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli, including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059. Alternate Names ERK; ERK-1; ERK-2; ERK1; ERK2; ERT1; ERT2; Extracellular signal-regulated kinase 1; Extracellular signal-regulated kinase 2; extracellular signal-regulated kinase-2; extracellular signal-related kinase 1; HS44KDAP; HUMKER1A; Insulin-stimulated MAP2 kinase; MAP kinase 1; MAP kinase 2; MAP kinase 3; MAP kinase isoform p42; MAP kinase isoform p44; MAPK 1; MAPK 2; MAPK 3; MAPK1; MAPK2; MAPK3; MGC20180; Microtubule-associated protein 2 kinase; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; Mitogen-activated protein kinase 3; MK01; MK03; p38; p40; p41; p41mapk; p42-MAPK; P42MAPK; p44-ERK1; p44-MAPK; P44ERK1; P44MAPK; PRKM1; PRKM2; PRKM3; protein tyrosine kinase ERK2 Specification REACTIVITY: H M R Hm Mk Mi Dm Z B Dg Pg Ce SENSITIVITY: Endogenous MW (kDa): 42, 44 Source/Isotype: Rabbit IgG